Balance Sheet
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Consolidated Net IncomeEBITEBITDAEBTEPS (Basic)EPS (Weighted Average and Diluted)Income from Continuing OperationsIncome towards Parent CompanyNet Income towards Common StockholdersNon Operating IncomeOperating ExpensesOperating IncomeOther Non Operating IncomeOther Operating ExpensesProfit After TaxResearch & DevelopmentRevenueSelling, General & AdministrativeShares Outstanding (Diluted Average)Shares Outstanding (Weighted Average)
Others
Ratios

Xenetic Biosciences (XBIO) Income from Continuing Operations (2023 - 2025)

Xenetic Biosciences' Income from Continuing Operations history spans 7 years, with the latest figure at 623027.0 for Q4 2025.

  • For Q4 2025, Income from Continuing Operations rose 43.32% year-over-year to 623027.0; the TTM value through Dec 2025 reached 2834582.0, up 32.58%, while the annual FY2025 figure was 2834582.0, 32.58% up from the prior year.
  • Income from Continuing Operations reached 623027.0 in Q4 2025 per XBIO's latest filing, down from 544734.0 in the prior quarter.
  • In the past five years, Income from Continuing Operations ranged from a high of 499473.0 in Q3 2024 to a low of 1337396.0 in Q2 2024.
  • Average Income from Continuing Operations over 3 years is 962893.75, with a median of 1020777.0 recorded in 2024.
  • The largest YoY upside for Income from Continuing Operations was 56.44% in 2024 against a maximum downside of 38.6% in 2024.
  • A 3-year view of Income from Continuing Operations shows it stood at 1255667.0 in 2023, then increased by 12.47% to 1099145.0 in 2024, then skyrocketed by 43.32% to 623027.0 in 2025.
  • Per Business Quant, the three most recent readings for XBIO's Income from Continuing Operations are 623027.0 (Q4 2025), 544734.0 (Q3 2025), and 724412.0 (Q2 2025).